拉米夫定治疗慢性乙型肝炎用药依从性及影响因素分析

Investigation on medical compliance in patients with chronic hepatitis B and an analysis of influence factors

采用问卷调查方法对163例使用拉米夫定的慢性乙型肝炎患者进行用药情况及影响因素调查。22．7％（37／163）的慢性乙型肝炎患者依从性较差，77．3％（126／163）的患者依从性较好，依从性较好患者的HBeAg、HBVDNA阴转率分别达78．6％（99／126）和46．0％（58／126），明显高于依从性差者，其仅为37．8％（14／37）和21．6％（8／37，P〈0．01）。说明慢性乙型肝炎患者用药依从性与其预后有关。

As to evaluating the medical compliance of patients with chronic hepatitis B （CHB） and the influence factors, information of 163 patients with CHB treated with lamivudine were collected by using the self-designed questionnaire, and the medical compliance and influencing factors of the patients were acquired by the research followed, and the prognosis and allocation were also observed. The results showed the medical compliance in 77.3% of patients with CHB was good, and in 22. 7% patients was poor. After following-up for 2 years, the negative rates of HBV DNA and HBeAg shown in patients with good medical compliance were 78.6% and 46.0% , respectively, showing a significantly higher rate than in those with poor medical compliance, which having thc rate of 37.8% and 21.6%, respectively （ P 〈 0. 01 ）. We suggested that there should be a correlation between the medical compliance of patients with CHB and the prognosis.